^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    apalutamide

    i
    Other names: ARN 509, JNJ56021927, JNJ-927, JNJ-56021927, ARN-509, ARN509, JNJ 56021927, JNJ927, JNJ 927
    Company:
    Generic mfg.
    Drug class:
    Androgen receptor antagonist
    Related drugs:
    2d
    Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial (clinicaltrials.gov)
    P2, N=532, Recruiting, Mayo Clinic | Trial completion date: May 2029 --> Feb 2031 | Trial primary completion date: May 2029 --> Feb 2031
    Trial completion date • Trial primary completion date
    |
    Xtandi (enzalutamide) • abiraterone acetate • Nubeqa (darolutamide) • apalutamide • triptorelin • goserelin acetate • Firmagon (degarelix) • Orgovyx (relugolix) • leuprolide acetate for depot suspension
    2d
    Phase I Trial of Apalutamide Plus Abiraterone Acetate, Docetaxel, and Prednisone in Patients With mCRPC (clinicaltrials.gov)
    P1, N=16, Completed, Weill Medical College of Cornell University | Active, not recruiting --> Completed | Trial completion date: Oct 2026 --> Oct 2025
    Trial completion • Trial completion date
    |
    CELLSEARCH®
    |
    docetaxel • abiraterone acetate • prednisone • apalutamide
    8d
    Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study (clinicaltrials.gov)
    P2, N=8, Active, not recruiting, University of Washington | Trial completion date: Apr 2026 --> Apr 2027
    Trial completion date
    |
    apalutamide • Simponi (golimumab)
    14d
    VA STARPORT: Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer (clinicaltrials.gov)
    P2/3, N=464, Recruiting, VA Office of Research and Development | Trial primary completion date: Mar 2026 --> Sep 2026
    Trial primary completion date
    |
    docetaxel • Xtandi (enzalutamide) • abiraterone acetate • prednisone • bicalutamide • apalutamide • triptorelin • goserelin acetate • flutamide • nilutamide • Firmagon (degarelix) • Orgovyx (relugolix) • leuprolide acetate for depot suspension
    17d
    2693-CL-2101: A Study to Learn How Enzalutamide, Apalutamide and Bicalutamide Affect the Way Fezolinetant is Processed by the Body in Men With Prostate Cancer (2024-520286-31-00)
    P1, N=56, Not yet recruiting, Astellas Pharma Global Development Inc.
    New P1 trial
    |
    Xtandi (enzalutamide) • bicalutamide • apalutamide
    21d
    A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer (clinicaltrials.gov)
    P1, N=300, Recruiting, Janssen Research & Development, LLC | Trial completion date: Sep 2027 --> May 2028 | Trial primary completion date: Jun 2026 --> Aug 2027
    Trial completion date • Trial primary completion date
    |
    docetaxel • Xtandi (enzalutamide) • abiraterone acetate • prednisone • Nubeqa (darolutamide) • cabazitaxel • apalutamide • cetrelimab (JNJ-63723283) • Pluvicto (lutetium Lu 177 vipivotide tetraxetan) • pasritamig (JNJ-8343)
    21d
    Double-DARE: A Study to Learn About Real-world Utilization and Outcomes of Darolutamide and Other Androgen Receptor Pathway Inhibitors (ARPIs) for Newly Diagnosed Metastatic Hormone-sensitive Prostate Cancer (de Novo mHSPC) in US Urology Clinics (clinicaltrials.gov)
    P=N/A, N=1400, Recruiting, Bayer | Trial completion date: Feb 2026 --> May 2026 | Trial primary completion date: Feb 2026 --> May 2026
    Trial completion date • Trial primary completion date • Real-world evidence
    |
    docetaxel • Xtandi (enzalutamide) • abiraterone acetate • Nubeqa (darolutamide) • apalutamide
    26d
    Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic Adenocarcinoma (clinicaltrials.gov)
    P2, N=102, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Feb 2026 --> Feb 2027 | Trial primary completion date: Feb 2026 --> Feb 2027
    Trial completion date • Trial primary completion date
    |
    CD4 (CD4 Molecule)
    |
    Oncotype DX Genomic Prostate Score® Assay
    |
    abiraterone acetate • prednisone • apalutamide
    28d
    Exploration of Treatment Effect of Novel Hormone Therapy Combined With Local Treatment Based on PSMA PET/CT Evaluation in mHSCP Patients (clinicaltrials.gov)
    P2, N=192, Recruiting, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Not yet recruiting --> Recruiting
    Enrollment open
    |
    abiraterone acetate • apalutamide • triptorelin • goserelin acetate • AiRuiEn (rezvilutamide)
    1m
    Active Surveillance With or Without Apalutamide Treatment in Low Risk Prostate Cancer (clinicaltrials.gov)
    P2, N=93, Completed, Institut Paoli-Calmettes | Unknown status --> Completed | N=206 --> 93
    Trial completion • Enrollment change
    |
    apalutamide
    1m
    PROTEUS: A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy (clinicaltrials.gov)
    P3, N=2517, Active, not recruiting, Janssen Research & Development, LLC | Trial primary completion date: Feb 2026 --> Dec 2026
    Trial primary completion date
    |
    apalutamide
    1m
    NCI-2018-01054: Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov)
    P2, N=7, Terminated, M.D. Anderson Cancer Center | Trial completion date: Apr 2027 --> Mar 2026 | Active, not recruiting --> Terminated | Trial primary completion date: Apr 2027 --> Mar 2026; <75% participation
    Trial completion date • Trial termination • Trial primary completion date
    |
    PTEN (Phosphatase and tensin homolog)
    |
    abiraterone acetate • apalutamide • Yonsa (abiraterone acetate)